HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed price. Currency in GBp
1,261.00
+42.50 (+3.49%)
At close: 4:42PM BST
Stock chart is not supported by your current browser
Previous close1,218.50
Open1,216.50
Bid1,231.00 x 16300
Ask1,280.00 x 34600
Day's range1,206.50 - 1,272.00
52-week range814.20 - 2,000.00
Volume554,896
Avg. volume805,387
Market cap3.037B
Beta0.70
PE ratio (TTM)N/A
EPS (TTM)-351.30
Earnings date14 Mar 2017 - 20 Mar 2017
Forward dividend & yield0.33 (2.75%)
Ex-dividend date2018-04-05
1y target est16.00
  • Reuters - UK Focuslast month

    BUZZ-Hikma: brokers raise ratings, PTs

    ** Jefferies raises recommendation on drugmaker to "hold" from "underperform" ** Despite challenging industry fundamentals persisting into 2018, guidance gives a floor to expectations, ...

  • Reuterslast month

    Drugmaker Hikma's FY profit, revenue meet expectations; shares rise

    The company has struggled due to persistent price pressures in the U.S. market and was forced to cut revenue guidance for its generics business thrice in 2017. Hikma's problems were further compounded by a delay in the launch of its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair. The U.S. Food and Drug Administration on Monday asked Hikma to conduct a further clinical study evaluating the drug.

  • Reuters - UK Focuslast month

    Drugmaker Hikma sees more layoffs in generics business

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is expected to cut more jobs in its generics business to save costs, the Jordan-based drugmaker said on Wednesday, after reporting full-year profit and revenue largely in line with expectations. Hikma, which was forced to cut revenue guidance for its generics business three times in 2017 due to pricing pressures in the United States, has cut 200 jobs since it bought the business from Boehringer Ingelheim in 2016, CFO Khalid Nabilsi said in a call to Reuters. Nabilsi added that another 200 jobs would go as a result of the consolidation of its generics' manufacturing facilities and U.S. distribution centres.

  • Reuters - UK Focus2 months ago

    FTSE 100 lags Europe on miners and energy, Just Eat goes cold

    Early gains for the FTSE 100 quickly dissipated and it was up just 0.1 percent by 0942 GMT, missing out on a rally lifting European stocks, with Germany's DAX up 0.7 percent. Falls in miners and oil majors had the biggest influence as the price of metals and crude fell.

  • Reuters - UK Focus2 months ago

    BUZZ-Hikma, Vectura: Shares down, generic Advair delayed again

    ** Shares of Hikma Pharmaceutical fall 6 pct at open, now down 2 pct, with Vectura down 5.3 pct ** Hikma fails to find quick resolution in dispute with U.S. FDA over plans to launch a generic copy of GlaxoSmithKline's ...

  • Reuters2 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.

  • Reuters - UK Focus2 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    GlaxoSmithKline (Other OTC: GLAXF - news) has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura, said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.

  • Reuters - UK Focus2 months ago

    Disappointing HSBC update, weak miners keep FTSE flat

    The FTSE index ended the session flat at 7,246.77 points, lagging a broadly positive European market, while Britain's mid-cap index added 0.8 percent, helped by news of a possible bid for software firm Fidessa. HSBC fell 3 percent after Europe's biggest lender by market value reported a jump in annual pre-tax profit that missed expectations and unveiled a plan to raise up to $7 billion over the next four months to bolster its capital base.

  • Reuters2 months ago

    Drugmaker Hikma names former Teva executive Olafsson as CEO; shares up

    Hikma said its current chairman and CEO, Said Darwazah, would become executive chairman. Shares of Hikma rose as much as 5 percent in early trading on the London Stock Exchange. Olafsson's appointment comes at a time when Hikma is facing higher price erosion levels than the rest of the industry that prompted it to lower the revenue guidance for its generics business twice last year.

  • Reuters3 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters - UK Focus3 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline (Other OTC: GLAXF - news) has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters3 months ago

    Drugmaker Dermapharm gears up for likely first German IPO of 2018

    German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens' (SIEGn.DE) healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.

  • Reuters - UK Focus3 months ago

    Drugmaker Dermapharm gears up for likely first German IPO of 2018

    German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens (BSE: SIEMENS.BO - news) ' healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.

  • Reuters - UK Focus4 months ago

    Hikma wins right to market Roche drug copy in Middle East and North Africa

    Dec (Shanghai: 600875.SS - news) 19 (Reuters) - Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday. The Jordan-based drugmaker agreed on the licensing deal with Celltrion to market the South Korea-based biopharmaceutical firm's Truxima, a copy of Roche's blockbuster blood cancer medicine, also known as MabThera. Truxima, the first biosimilar cancer drug to hit the European market in February, is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and and microscopic polyangiitis.

  • Reuters5 months ago

    Takeaway app Delivery Hero joins European index in tech-heavy rejig

    German takeaway app Delivery Hero, which listed five months ago, will join the STOXX 600 benchmark index in December as rapidly rising tech stocks dominate its quarterly reshuffle. Delivery Hero's stock is up by around 40 percent from its IPO price, raising its market capitalisation to 6.7 billion euros ($7.9 billion). Along with companies such as Just Eat, which is expected to be promoted to Britain's FTSE 100 index later on Wednesday, Delivery Hero's addition reflects consumer demand for cheap, efficient, on-demand services to order food.

  • Reuters - UK Focus6 months ago

    European shares suffer worst day since June as earnings underwhelm

    MILAN/LONDON, Nov 9 (Reuters) - European shares fell on Thursday as a series of underwhelming earning updates, including from industrial giant Siemens, prompted investors to take profits out of a market still trading near two-year highs. The pan-European STOXX 600 benchmark index fell 1.1 percent, suffering its biggest daily loss since end-June, while Germany's DAX fell 1.5 percent. The STOXX 600 is up 7.9 percent so far this year following a rally that has been fuelled by a combination of strong economic data, solid earnings and easing political fears.

  • Reuters - UK Focus6 months ago

    Britain's FTSE under pressure as Burberry revamps its strategy

    A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus. Britain's blue-chip FTSE 100 index was flat in percentage ...

  • Reuters6 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    The dispute between the Jordan-based firm, its partner Vectura (VEC.L) and the U.S FDA delays any eventual approval of the generic version of the drug. Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters - UK Focus6 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters6 months ago

    Hikma, Vectura in dispute with FDA over generic Advair

    LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...

  • Reuters - UK Focus6 months ago

    Drugmaker Hikma cuts generics sales forecast a third time

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday lowered 2017 revenue guidance for its generics business for a third time. The Jordan-based firm, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business. In August it had lowered its generics revenue guidance by $50 million to about $620 million, having slashed it to $670 million from an initial $800 million last November.

  • Forbes6 months ago

    The U.S. Has A Fentanyl Shortage ... In The Clinic, Not On The Streets

    I fear this means I need to bring my own to my follow-up colonoscopy in November.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes